NCT00385853 - PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Glioblastoma

Interventions

DRUG

PTK787/ZK 222584

Twice daily for each 28-day cycle

DRUG

Temozolomide

Daily for each 28-day cycle

PROCEDURE

Radiation Therapy

For 7 weeks beginning on day 5 of the first treatment cycle

Trial Locations (2)

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston